Drug maker Novartis AG (NOVN.CH) is in advanced talks to acquire MorphoSys AG (MOR.DE), two people familiar with the matter told Reuters on Monday.
The sources added that there is no certainty that negotiations on the deal will be successful and asked to remain anonymous as the matter is confidential. They declined to provide any information on the acquisition price.
Start investing today or test a free demo
Create account Try a demo Download mobile app Download mobile appMorphoSys shares are currently gaining nearly 37%.
Source: xStation
This content has been created by XTB S.A. This service is provided by XTB S.A., with its registered office in Warsaw, at Prosta 67, 00-838 Warsaw, Poland, entered in the register of entrepreneurs of the National Court Register (Krajowy Rejestr Sądowy) conducted by District Court for the Capital City of Warsaw, XII Commercial Division of the National Court Register under KRS number 0000217580, REGON number 015803782 and Tax Identification Number (NIP) 527-24-43-955, with the fully paid up share capital in the amount of PLN 5.869.181,75. XTB S.A. conducts brokerage activities on the basis of the license granted by Polish Securities and Exchange Commission on 8th November 2005 No. DDM-M-4021-57-1/2005 and is supervised by Polish Supervision Authority.
